EU PIP breast implant withdrawal

By Agung Purnama and Daniela Drago2019-10-01T15:31:00

The Poly Implant Prothèse (PIP) silicone breast implant failures had a socioeconomic impact at an international level, affecting nearly 400,000 patients in 55 different countries,[1] and resulted in major EU regulatory updates. PIP was a French company founded in 1991 and it produced approximately two million sets of silicone breast ...

How to read this article

Thank you for visiting Regulatory Rapporteur, you have now used up your free accesses.

To continuing reading you can register for free, join TOPRA, or if you are a member login now.

REGISTER FOR FREE

1. Free access to selected content

Register to continue to access industry news, podcasts and commentary plus one member-only journal article each month. You will still be able to view editorials and contents pages without restriction.

Create your own library to save your favourite content.
Sign up for Regulatory Rapporteur email newsletters.

Create a free account

Members login

2. Included with TOPRA membership

Already a TOPRA member?

Using your MyTOPRA credentials, log-in now for unlimited access to all Regulatory Rapporteur journal articles, online archive and the latest industry news and content.

JOIN TOPRA

3. TOPRA membership

Become a TOPRA member and join our global regulatory affairs community.

Great savings on our events and training.
Be part of our dynamic international community.
Contribute to the profession.
Grow your skills and knowledge.
Take your career to the next level.

Become a member